“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey

See related editorial by Lundebjerg et al.

Detalles Bibliográficos
Autores principales: Padovani, Alessandro, Caratozzolo, Salvatore, Rozzini, Luca, Pilotto, Andrea, Benussi, Alberto, Tedeschi, Gioacchino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Regular Issue Content
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298825/
https://www.ncbi.nlm.nih.gov/pubmed/34750815
http://dx.doi.org/10.1111/jgs.17530
_version_ 1784750800465035264
author Padovani, Alessandro
Caratozzolo, Salvatore
Rozzini, Luca
Pilotto, Andrea
Benussi, Alberto
Tedeschi, Gioacchino
author_facet Padovani, Alessandro
Caratozzolo, Salvatore
Rozzini, Luca
Pilotto, Andrea
Benussi, Alberto
Tedeschi, Gioacchino
author_sort Padovani, Alessandro
collection PubMed
description See related editorial by Lundebjerg et al.
format Online
Article
Text
id pubmed-9298825
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-92988252022-07-21 “Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey Padovani, Alessandro Caratozzolo, Salvatore Rozzini, Luca Pilotto, Andrea Benussi, Alberto Tedeschi, Gioacchino J Am Geriatr Soc Regular Issue Content See related editorial by Lundebjerg et al. John Wiley & Sons, Inc. 2021-11-09 2022-02 /pmc/articles/PMC9298825/ /pubmed/34750815 http://dx.doi.org/10.1111/jgs.17530 Text en © 2021 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Regular Issue Content
Padovani, Alessandro
Caratozzolo, Salvatore
Rozzini, Luca
Pilotto, Andrea
Benussi, Alberto
Tedeschi, Gioacchino
“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
title “Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
title_full “Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
title_fullStr “Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
title_full_unstemmed “Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
title_short “Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
title_sort “real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
topic Regular Issue Content
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298825/
https://www.ncbi.nlm.nih.gov/pubmed/34750815
http://dx.doi.org/10.1111/jgs.17530
work_keys_str_mv AT padovanialessandro realworldeligibilityforaducanumabdependsonclinicalsettingandpatientsjourney
AT caratozzolosalvatore realworldeligibilityforaducanumabdependsonclinicalsettingandpatientsjourney
AT rozziniluca realworldeligibilityforaducanumabdependsonclinicalsettingandpatientsjourney
AT pilottoandrea realworldeligibilityforaducanumabdependsonclinicalsettingandpatientsjourney
AT benussialberto realworldeligibilityforaducanumabdependsonclinicalsettingandpatientsjourney
AT tedeschigioacchino realworldeligibilityforaducanumabdependsonclinicalsettingandpatientsjourney

Ejemplares similares